TriSalus Life Sciences 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 revenue was $12.9 million, up approximately 11% from $11.6 million in the prior-year period and approximately 13% sequentially from $11.4 million in the second quarter, driven by increasing TriNav adoption.
- Gross margin was 86%, compared with 84% in the prior-year period.
- Research and development expenses were approximately $3.2 million, compared with $5.7 million in the prior-year period; sales and marketing expenses were approximately $10.7 million, compared with $6.8 million; and general and administrative expenses were approximately $4.9 million, compared with $6.1 million.
- Adjusted EBITDA loss was approximately $4.7 million, compared with $5.4 million in the third quarter of 2025, and the company ended the quarter with approximately $41 million in cash.
- Management said revenue growth was below expectations, primarily because new expansion territories took longer than anticipated to ramp, alongside a faster-than-anticipated shift toward super-selective Y-90 administration in small distal vessels.
- The number of accounts ordering TriNav increased double digits year over year, and September was the strongest month of the year for ordering accounts and total units sold.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Thank you for standing by. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome to the TriSalus Life Sciences third quarter 2026 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad. If you would like to withdraw your question, press the star key. Thank you. I would now like to turn the call over to Mary Szela, CEO.
Please go ahead. Good morning, and thank you for participating in today's call.
Joining me from TriSalus are Mary Szela, President and Chief Executive Officer, David Patience, Chief Financial Officer, and Dr. Richard Marshall, Chief Medical Officer. Earlier today, TriSalus issued a press release announcing financial results for the quarter ended September 30, 2026. A copy of the press release is available on the Investor Relations section of the company's website. Before we begin, I'd like to remind you that management will make remarks during this call that include forward-looking statements within the meaning of federal securities laws, and that these are being made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements.
These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a description of the risks and uncertainties associated with our business, please refer to the Risks Factors section of our Forms 10-Q and 10-K on file with the SEC and available on EDGAR, as well as our other periodic filings. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, November 10, 2026. TriSalus disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. With that, I will turn the call over to Mary.
Good morning, and thank you all for joining us. The third quarter marked an important period of growth and advancement for TriSalus. We drove increasing revenue, both year-over-year and quarter-over-quarter, as our commercial expansion continued and account utilization improved. In addition, in September, we received FDA clearance for TriNav Advance, enabling us to expand our portfolio looking forward. TriNav Advance extends our pressure-enabled drug delivery approach, called PEDD, to small distal vessels through the microcatheter of the physician's choice. These are vessels that TriNav technology could not previously fully address. With TriNav Advance, we now can address the full range of vessels encountered in liver embolization procedures. That means interventional radiologists can keep their preferred workflow while patients still benefit from PEDD. We are now preparing for a limited market release of TriNav Advance to gather early clinical and customer feedback before a broader launch.
Milestones like this matter because of the problem we set out to solve. Catheter-based oncology drug delivery has changed very little in decades, even as therapies themselves have advanced dramatically. TriNav was designed to close that gap, enabling interventional radiologists to deliver therapy to the tumor with enhanced perfusion, greater precision and concentration, and avoidance of off-target delivery. Across liver embolization and the additional indications we're pursuing, we see a U.S. addressable market of approximately $2.5 billion, and we're still in the early stages of capturing it. Turning back to our results, total revenue for the third quarter was $12.9 million, up approximately 11% from $11.6 million in the prior year period, and up approximately 13% sequentially from $11.4 million last quarter, driven by increasing adoption of TriNav.
While growth came in below our expectation, this reflects the timing of our commercial organization transition and new account ramp, in addition to a faster-than-anticipated shift towards super-selective Y90 administration in small distal vessels, a trend we are watching closely and preparing to address through the launch of TriNav Advance. Looking forward, our plan to accelerate growth starts with our commercial organization. As a reminder, we more than doubled our footprint over the first half of the year to better capture the full scope of the opportunity in front of us. We continue to believe this was the right decision for the long-term growth of TriSalus. Performance in our existing territories continue to grow, and the shortfall relative to the plan in Q3 was concentrated in our new expansion territories, where new representatives are taking slightly longer than anticipated to reach full productivity.
As these representatives continue to build relationships with interventional radiologists and integrate TriNav into established procedural workflows, we expect their productivity to steadily improve. In addition, during the third quarter, we saw a faster-than-anticipated shift towards super selective Y90 administration in small distal vessels, a trend that accelerated beyond what we observed in the first half of the year, and that we could not fully address until the recent clearance of TriNav Advance. With TriNav Advance, we now have a solution and have access to those procedures. Even with these dynamics, we're already seeing early signs of progress as our new sales funnel builds. In the third quarter, the number of accounts ordering TriNav increased double digits year-over-year, and September was our strongest month of the year for both ordering accounts and total units sold.
Territories led by our newer representatives also grew unit volume sequentially, demonstrating a positive, albeit slower than expected trend line. We are focused on converting procedures to use TriNav within this growing account base and improving productivity across our expansion territories, and we believe our team is well-positioned to drive growth acceleration as we move into 2027. We're also encouraged by recent changes in the reimbursement landscape. On November 4, CMS published its calendar year 2027 final rules, which include two updates that were favorable for TriSalus. First, in the calendar year 2027 Hospital Outpatient Prospective Payment System, or OPPS, final rule, the Centers for Medicare & Medicaid Services, CMS, finalized the reassignment of HCPCS code C8004, the Y90 simulation, or known as mapping angiogram, from APC 5193 to APC 5194, aligning it with C9797, which is already assigned to APC 5194.
Based on the final rule, the national Medicare payment for procedures billed under C8004 will increase from approximately $11,874 to approximately $20,910, an increase of approximately 76%, effective January 1, 2027. Our core hospital payment is also maintained. C9797, the PEDD embolization procedure, remains in APC 5194, with payment increasing from approximately $18,729 in 2026 to approximately $20,910 in 2027. The catheter code C1982 remains included in the procedural payment. Second, CMS established national pricing for G0577, the new code for PEDD embolization in the physician office setting, commonly referred to as an office-based lab, or OBL, at approximately $13,788 per procedure, up from approximately $12,300 in the proposed rule. The new national rate is effective January 1, 2027, replacing pricing previously set by each Medicare contractor.
Treatment for patients with certain liver cancers, including both TACE and TARE procedures, continue to migrate from traditional hospital settings into OBLs, which offer patients more accessible, community-based care with shorter wait times and more flexible scheduling. We believe national pricing for G0577 will meaningfully expand access to PEDD in this growing site of care and give clinicians more flexibility in where and how they practice. These decisions recognize the resource intensity and distinct mechanism of TriNav-enabled procedures and provides a stronger reimbursement foundation for hospitals as we continue to expand adoption of TriNav. Taken together, these decisions give PEDD a payment path in every site of care, including hospital outpatient, ambulatory surgery center, and the office-based lab, heading into our 2027 OBL launch. Our second priority remains demonstrating and validating the value of PEDD to drive greater awareness and adoption.
As we continue to build our evidence program, we've organized it around three questions that ultimately determine whether a physician and the site they practice in adopts a new technology. First, TriNav, does it perform better than what I use today? Second, which of my patients benefit the most from TriNav? Third, does it make economic sense for my institution to adopt TriNav? Each of our studies is designed to answer one of these questions, and they build on one another. We use real-world and retrospective data to identify signals cost-efficiently and confirm those signals in rigorous, prospective, head-to-head studies at leading academic centers. Today, we have 11 active studies across 27 clinical sites with more than 400 patients treated with TriNav. Let me start with the first question. Is TriNav better than standard of care? This is where we are investing most heavily.
We view the liver embolization market as three distinct segments: hepatocellular carcinoma, or HCC, liver metastases, and neuroendocrine tumors. Our strategy is to win in each one, and to do that, we're building a foundational prospective study in each segment that compares TriNav head-to-head with a standard microcatheter. In liver metastases, our PRESSURE study at Stanford is a randomized study that compares TriNav with standard delivery in TARE. Measuring tumor absorbed dose, response rate, and disease control. In neuroendocrine tumors, we are launching a multicenter case study in collaboration with University of Pennsylvania, a recognized leader in both liver embolization and neuroendocrine tumor care. It compares TriNav head-to-head with a standard microcatheter and expands an earlier pilot study that showed positive results for TriNav. In HCC, we have two retrospective studies underway examining TriNav-delivered care.
These findings will inform the design of our prospective PEAR study comparing tumor response with TriNav versus a standard microcatheter. Physicians have told us tumor response is the endpoint that matters most in their decision to adopt. We look to initiate both the neuroendocrine and the HCC studies by year-end. Together with PRESSURE, these three studies are designed to give physicians rigorous comparative evidence across every segment of the liver market. Our completed studies add to this foundation. At Massachusetts General Hospital, the randomized PETER study evaluated TriNav's effect on the tumor-to-normal ratio in HCC and hypovascular tumors and has been submitted for peer-reviewed publication that should be published this year. We believe its publication can be a meaningful commercial catalyst. Underpinning all of our evidence generation initiatives is our commitment to patient safety.
It is worth noting that since the initial launch of TriNav in 2020, we have a reportable safety event rate of just 0.02% across nearly 20,000 device patient uses. This is a tremendous validation of the consistency and safety of TriNav. That brings me to the second question: Which patients benefit most? Showing that TriNav performs better is the foundation. Defining where it performs best helps physicians select the right patients and moves PEDD from an option to a routine part of their practice. At MD Anderson, PREDICTT continues to enroll. It is a prospective study of PEDD in hypovascular tumors, a population that is difficult to treat with a standard microcatheter, and we continue to expect enrollment to take approximately 12 to 18 months. Our two retrospective studies of TriNav-delivered care in HCCs are progressing, with analysis ongoing in one and the manuscript being finalized in the other.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
